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Abstract 
Objective: The objective of this selective EBM review is to determine whether or not 
pembrolizumab has an effect on prolonging overall survival in patients with non-small 
cell lung cancer expressing programmed death ligand-1 (PD-L1).  
 
Study Design: Review of two randomized controlled trials and one cohort study 
published in English in peer review journals.  
 
Data Sources: Two randomized controlled trials and one cohort study, which evaluated 
the efficacy of pembrolizumab on non-small cell lung cancer with PD-L1 expression 
compared to chemotherapy. All studies were found in PubMed database.  
 
Outcomes Measured: Overall survival measured by Kaplan-Meier analysis of overall 
survival. 
 
Results: Both of the RCT (Reck 2016 and Herbst 2016) showed pembrolizumab to be 
statistically effective in prolonging overall survival in patients with NSCLC expressing 
PD-L1 (p=0.005 and p<0.0001 respectively). Both studies showed a higher increase in 
overall survival in patients treated with pembrolizumab compared to those treated with 
traditional chemotherapy. In the cohort study conducted by Goldberg (2016), overall 
survival was measured to be 7.7 months (95% CI). Pembrolizumab also showed to have a 
positive effect on brain metastases as well.  
 
Conclusions: All studies included in this systematic review indicate that pembrolizumab 
is effective in prolonging overall survival in patients with NSCLC expressing PD-L1.  
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Introduction 
 Lung cancer is one of the most common cancers in the world. Symptoms typically 
do not present until the disease has advanced. Lung cancer is characterized by coughing, 
hemoptysis, dyspnea, chest pain, and weight loss. It is categorized into small cell lung 
cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC accounts for 80-85% 
of all lung cancer. NSCLC includes adenocarcinoma, squamous cell carcinoma, large cell 
carcinoma, and other rare subtypes such as adenosquamous carcinoma and sarcomatoid 
carcinoma.1 This paper evaluates two randomized controlled trials (RCT) and one cohort 
study comparing the efficacy of pembrolizumab in treating NSCLC with the efficacy of 
the traditional chemotherapy treatments.  
 In 2017, there have been 222,500 reported new cases of lung cancer and 155,870 
deaths from lung cancer.2 It carries the highest mortality rate compared to other cancers, 
as it is responsible for 25% of cancer deaths.2 The largest risk factor is tobacco use. 
Studies have shown that an average male smoker has a 9 to 10 -fold risk for developing 
lung cancer. The duration of smoking and the number of cigarettes smoked per day plays 
a key role in determining the increased risk for lung cancer.3  
 The cost of managing lung cancer is a heavy burden for most patients. The 
number of healthcare visits increase remarkably with the diagnosis of lung cancer and 
patients are frequently admitted to a hospital. In a study conducted by Vera-Llonch et al. 
patients with metastatic lung cancer receiving chemotherapy revealed an average of 1.5 
hospital admissions, 8.9 days spent as inpatient, and 69 outpatient visits over the course 
of 334 days.4 The same study revealed a total healthcare cost of $125,849 over the course 
of 334 days. The total cost was broken down to reveal the following: outpatient care was 
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responsible for 34% of the total cost, inpatient care was responsible for 20%, 
chemotherapy was responsible for 22%, and other outpatient medications were 
responsible for 24% of the total costs. 
 NSCLC is typically treated with surgical resection if indicated and chemotherapy. 
Chemotherapy is typically combined with an active cytotoxic agent. Common drugs used 
for treatment include cisplatin, carboplatin, docetaxel, and paclitaxel.5 These treatments 
have shown to be effective initial treatments for NSCLC. However, these treatments may 
not work in certain patients with evolving disease. Recently, research relating to targeting 
specific receptor pathways has led to the development of immunomodulating drugs. In 
these trials, the programmed cell death protein 1 (PD-1) pathways have been targeted as 
the PD-1 receptor has shown to be an immune checkpoint inhibitor.6 When the PD-1 
receptors on B and T cells bind with PD-L1 and PD-L2 ligands on tumor cells, it leads to 
a suppression of T cells via a negative feedback loop.6 The tumor cells are then 
unrecognized in the body’s immune response. Pembrolizumab is an IgG4 monoclonal 
antibody that targets the PD-1 receptor pathway.6 The antibody binds to the PD-1 
receptor on B and T cells and prevent the binding to PD-L1 ligands expressed on tumor 
cells. An estimated 23-28% of all patients with NSCLC are found to have PD-L1 
expression.7 Pembrolizumab may be more effective than cytotoxic chemotherapy in 
prolonging overall survival for these patients. 
Objective 
 The objective of this systematic review is to determine whether or not 
pembrolizumab has an effect on prolonging overall survival in patients with non-small 
cell lung cancer expressing programmed death ligand-1 (PD-L1).  
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Methods 
 This systematic review evaluates two randomized controlled trials and one cohort 
study. There were specific criteria used for the selection of these studies. The population 
of the studies targeted men and women over the age of 18 years with NSCLC with PD-L1 
expression. The intervention used in the studies was intravenous pembrolizumab of 
various doses. The comparisons in the studies were various combination chemotherapy 
treatments including carboplatin, cisplatin, pemetrexed, gemcitabine, paclitaxel, and 
docetaxel. The primary outcome measured in the studies was overall survival of the 
patients.  
 The studies were obtained via PubMed and they were selected based on relevance 
to my research topic and the inclusion of patient oriented outcomes. The inclusion criteria 
used during the selection of the articles were as follows: studies that were published 
within the past 7 years and the inclusion of patient oriented outcomes – overall survival.  
The exclusion criteria were patients under the age of 18 years old.  All articles were 
published in English and were published in peer-reviewed journals. Key words used to 
search for the articles included pembrolizumab and non-small cell lung cancer. The 
summary of statistics was reported via ARR, NNT, and p-value. The demographics and 
characteristics of the included studies are outlined in Table 1.   
Table 1: Demographics & Characteristics of included studies 
 
Study Type # Pts Age 
(yr) 
Inclusion Criteria Exclusion Criteria W/D Interventions 
Herbst6 RCT 1034 >18 Pt 18 years and older 
with NSCLC;Previous 
tx of 2 or more cycles 
of platinum-doublet 
chemotherapy;Tx of 
tyrosine kinase 
inhibitor for pt with 
EGFR-sensitizing 
Previous tx with PD-
1 checkpoint 
inhibitors or 
docetaxel; 
Pt with active brain 
metastases or 
carcinomatous 
meningitis; 
60 Pembrolizumab 10 
mg/kg IV over 30 
min q 3 wks 
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mutation/ALK gene 
rearrangement; 
Eastern cooperative 
Oncology Group 
(EOCG) performance 
status of 0 or 1; 
PD-L1 expression on 
at least 1% of tumor 
cells  
Pt with autoimmune 
disease that requires 
systemic steroids; 
Pt with interstitial 
lung disease or hx of 
pneumonitis that 
requires systemic 
steroids 
Reck7 RCT 305 >18 Pt 18 years and older 
w/ stage IV NSCLC 
w/o sensitizing EGFR 
mutation or ALK 
translocation; No 
previous systemic 
therapy for metastatic 
ds; EOCG score of 0 
or 1; at least 1 
measurable lesion per 
Response Evaluation 
Criteria in Solid 
Tumors (RECIST); 
Life expectancy of at 
least 3 months; 
PD-L1 tumor 
proportion score of 
>50%  
Pt receiving systemic 
glucocorticoids or 
other 
immunosuppressive 
tx; 
Pt w/ untreated brain 
metastases; 
Pt received systemic 
tx for autoimmune 
disease in the past 2 
yrs; 
Pt with interstitial 
lung disease; 
Pt received 
glucocorticoids for 
pneumonitis  
1 Pembrolizumab 
200 mg  IV q 35 
wks for 35 cycles  
Goldberg8 Cohort 36 >18 Pt 18 yo and older w/ 
stage IV melanoma or 
NSCLC; 
At least 1 untreated 
brain metastasis 
between 5mm and 20 
mm; 
ECOG performance 
status of 0-1; 
Life expectancy  >3 
months; 
Adequate organ 
function 
Pt w/ neurological sx 
attributable to brain 
metastasis; 
Use of corticosteroids 
to control 
neurological sx or 
perilesional edema; 
Pt w/ leptomeningeal 
disease or 
autoimmune disease; 
Previous tx of PD-1 
or PD-L1 targeting 
agents 
12 Pembrolizumab 10 
mg/kg IV q 2 wks  
 
Outcomes 
 The primary outcome measured in these studies was overall survival of the 
patients with non-small cell lung cancer treated with pembrolizumab. This was measured 
and analyzed using the Kaplan-Meier analysis of overall survival.  
Results 
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 In a study conducted by Reck et al., 305 patients with untreated advanced NSCLC 
with PD-L1 expression were randomly assigned with either pembrolizumab or a 
platinum-based chemotherapy.7 There were a total of 154 patients in the pembrolizumab 
group and 151 patients in the chemotherapy group. The most common chemotherapy 
regimen used was carboplatin plus pemetrexed (67 out of 151 patients). Crossover from 
the chemotherapy group to the pembrolizumab group was allowed depending on disease 
progression. At the end of the trial, 66 patients from the chemotherapy group had crossed 
over to receive pembrolizumab after showing signs of disease progression.  
 At 6 months, 80.2% (95% CI, 72.9 to 85.7) of patients in the pembrolizumab 
group were still alive compared to 72.4% (95% CI, 64.5 to 78.9) of overall survival in the 
chemotherapy group. Patients receiving pembrolizumab had significantly longer overall 
survival compared to those receiving chemotherapy by the end of the trial. The hazard 
ratio for death was calculated to be 0.60 with a 95% CI, 0.41 to 0.89; P= 0.005. The NNT 
calculated was 13 (see Table 2), indicating that 13 people are needed to treat in order for 
1 person to have longer overall survival after 6 months of pembrolizumab.  
 
Table 2. Efficacy in pembrolizumab in prolonging overall survival in patients with 
advanced NSCLC as measured by Reck 2016 
Study Relative 
benefit 
increase (RBI) 
Absolute 
benefit 
increase (ABI) 
Number 
needed to 
treat (NNT) 
P-value Confidence 
Interval (CI) 
Reck (2016) 0.108 0.078 13 0.005 95% CI, 
0.41 – 0.89 
 
In another study conducted by Herbst et al., 689 patients with previously treated 
NSCLC and PD-L1 expression were randomly assigned to pembrolizumab and 
docetaxel.6 There were 346 patients assigned to pembrolizumab and 343 patients 
assigned to docetaxel. Patients receiving pembrolizumab had longer overall survival than 
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those receiving docetaxel. The median overall survival was 12.7 months (95% CI, 10.0-
17.3) for those receiving pembrolizumab and 8.5 months (95% CI, 7.5-9.8) for those 
receiving docetaxel. The 1 year overall survival was 52.3% for those receiving 
pembrolizumab and 34.6% for those receiving docetaxel. The hazard ratio for 
pembrolizumab 10 mg/kg vs. docetaxel was 0.61 with a 95% CI (0.49-0.75) and 
p<0.0001. The NNT was calculated to be 10 (see Table 3).  
Table 3. Efficacy of pembrolizumab 10 mg/kg in prolonging overall survival in 
patients with advanced NSCLC as measured by Herbst 2016 
Study Relative benefit 
increase (RBI) 
Absolute benefit 
increase (ABI) 
Number needed to 
treat (NNT) 
Herbst 2016 0.249 0.109 10 
 
 Goldberg et al. conducted a cohort study in which they followed 18 patients with 
NSCLC that were positive for PD-L1 expression and had untreated brain metastases.8 
They were treated with 10 mg/kg of pembrolizumab every 2 weeks and data were 
collected at 12 months. They measured brain metastases response to pembrolizumab as 
well as overall survival. At 12 months, 6 out of 18 enrolled patients showed brain 
metastasis response (33%; 95% CI, 14-59). Median overall survival was calculated to be 
7.7 months with a 95% CI (3.5 – not reached). By the 12 month follow up, 8 patients 
have died from disease progression and 1 patient died from unknown reasons. Adverse 
reactions to treatments included grade II acute kidney injury via interstitial nephritis, 
grade III pneumonitis, grade III colitis, and grade IV hyperkalemia.  The patient with 
grade III colitis discontinued treatment of pembrolizumab. There were no treatment 
related deaths reported. The study is still on going and they plan on publishing more 
reports as the data matures.   
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Discussion 
 A diagnosis of lung cancer carries heavy weight considering it has the highest 
mortality rate compared to other types of cancers. Although surgical resection and 
combination chemotherapy treatments are effective in treatment of most lung cancers, 
there still remains a population of patients with advanced disease that do not benefit from 
traditional therapy. As medical research advances and alternative treatment options such 
as pembrolizumab arise, patients are given the opportunity to remain hopeful and prolong 
overall survival. This systematic review encompasses studies that display the therapeutic 
benefits of using PD-L1 as a biomarker for therapy. These studies are also among the first 
to use PD-L1 as a biomarker. The patient populations that experience therapeutic benefits 
from pembrolizumab are those with advanced NSCLC who express PD-L1.  
It is important to note the adverse effects related to pembrolizumab in comparison 
to those related to traditional chemotherapy. In the study conducted by Reck et al., 
adverse effects related to pembrolizumab occurred in 73.4% of the patients while 90% of 
those receiving chemotherapy experienced treatment related adverse effects.7 The most 
common adverse effects from pembrolizumab were reported to be diarrhea, fatigue, and 
pyrexia. The most common adverse effects from chemotherapy were anemia, nausea, and 
fatigue. In the study conducted by Herbst et al., adverse effects related to pembrolizumab 
occurred in 66% of patients receiving 10 mg/kg compared to 81% of patients receiving 
docetaxel.6 In both studies, immune related adverse effects occurred more in those 
receiving pembrolizumab. The most common immune related adverse effects were 
hypothyroidism, pneumonitis, and hyperthyroidism. Hypothyroidism affected 8% of 
those receiving pembrolizumab compared to <1% of those receiving docetaxel. 
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Pneumonitis affected 4-5% of those receiving pembrolizumab compared to 2% of those 
receiving docetaxel. Hyperthyroidism affected 4-6% of those receiving pembrolizumab 
compared to 1% of those receiving docetaxel6.  
Brain metastases occur in 10% of patients with NSCLC. 9 There is a poor outcome 
for patients diagnosed with brain metastases from NSCLC. A median overall survival 
length of 4 months has been shown in patients treated with whole brain radiation therapy 
(WBRT). 9 The study conducted by Goldberg et al., demonstrated a positive response of 
brain metastases from NSCLC from pembrolizumab with a median overall survival of 7.7 
months. 8 As this is a cohort study, it does not allow for the comparison of the overall 
survival value. Another limitation is the low enrolled patient numbers in the study. As 
this study is ongoing, comparison of overall survival in those being treated with 
pembrolizumab and those treated with WBRT should be completed.  
Conclusion 
 Pembrolizumab shows to be effective in prolonging overall survival compared to 
traditional chemotherapy in these studies. For patients who express PD-L1 with advanced 
NSCLC, this could be indicated as first-line therapy. Pembrolizumab can also be used in 
those who failed combination chemotherapy treatments as well. Further evaluations on 
pembrolizumab’s adverse effects could be studied in the future. The studies chosen in this 
systemic review indicate fewer adverse effects associated with pembrolizumab compared 
to traditional chemotherapy treatments. The quality of life in those extra months of 
survival is of great importance.  As pembrolizumab becomes indicated as first-line 
therapy for these patients, adverse effects should continue to be monitored and studied.  
For patients who express PD-L1 with advanced NSCLC with brain metastases, the 
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ongoing data collection should compare median survival in patients with brain metastases 
being treated by various methods such as WBRT. Further research with larger population 
sizes and randomized controlled trials are needed to compare overall survival in patients 
with brain metastases.  
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